US FDA Rebukes Another Sponsor For Touting Investigational Product Based On Subgroup Efficacy

 
• By Sue Sutter
  
Rosy picture
The FDA has issues with CytoDyn's rosy picture of leronlimab efficacy in treating COVID. • Source: Alamy
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D